Project Grant R03AG087483
- This federal Project Grant award for $831,583 was provided by the National Institute on Aging (CFDA 93.866 Aging Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on "Characterizing Microvascular Impairment in Adults with Elevated Genetic Risk for Alzheimer's Disease." The project aims to elucidate the physiological mechanisms by which the APOE-E4 genetic risk factor contributes to microvascular impairment,...
- This federal Project Grant award of $459,250.00 from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) is focused on investigating the impact of stress and resilience on the longitudinal trajectories of Alzheimer's disease (AD)-related brain pathology and cognitive function. The research aims to elucidate the mechanisms by which stress may predispose individuals to long-term cognitive changes and the development of AD. The awardee, The General Hospital...
- This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,173,794 to The General Hospital Corporation (Massachusetts General Hospital) to conduct research on enhancing brain resilience to Alzheimer's disease by targeting adult hippocampal neurogenesis. The project aims to explore the mechanisms by which adult hippocampal neurogenesis cooperates with brain-derived neurotrophic factor (BDNF) to potentially slow cognitive decline in...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) will support a $185,074 research study conducted by the University of California, Berkeley. The goal of the study is to examine how brain network connectivity is associated with Alzheimer's disease (AD) risk, longitudinal pathology accumulation, and aging. The researchers will use positron emission tomography (PET) imaging and resting-state functional MRI (rs-fMRI) to investigate the mechanisms of how...
- The National Institute on Aging awarded a $4.6 million Project Grant to Cornell University under the Aging Research program (CFDA 93.866) to develop new imaging techniques for measuring microvascular blood flow in Alzheimer's disease and related dementia models. The award will support the design of an adaptive excitation source for 2-photon and 3-photon fluorescence microscopy to simultaneously measure blood flow speeds in approximately 300 cortical or 50 deep white matter microvessels. This...
- This federal Project Grant award of $152,237.00 was provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866). The grant supports research to investigate neuromuscular adaptation to exercise in the early stages of Alzheimer's disease (AD). The project aims to determine the neuromuscular adaptive response to endurance exercise training in AD mouse models before the onset of overt AD-like pathology. Key objectives include assessing mitochondrial...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $455,009 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop a novel [18F]-labeled amphiphilic PET probe that can cross the blood-brain barrier and track CD206+ microglia/macrophages in Alzheimer's disease. The goal is to create a non-invasive imaging method to detect anti-inflammatory M2-like microglia and macrophages, which play a key role in...
- This Project Grant award from the National Institute on Aging (NIA) under CFDA 93.866 Aging Research provides $812,030 to develop and optimize non-invasive imaging biomarkers to track neuroinflammation in the early stages of Alzheimer's disease (AD). The research aims to investigate the relationship between astrocytic acetate metabolism and astrocyte reactivity, characterize spatiotemporal patterns of neuroinflammation and brain glucose hypometabolism in an AD mouse model, and validate the...
- The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $129,330 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on profiling and forecasting individual progression in Alzheimer's disease and related dementias (ADRD). The key objectives of this 5-year project are to: 1) deploy a multi-modal information framework that leverages decades-long in vivo and digital...
- The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $167,940 project grant to The Children's Hospital Corporation (Boston Children's Hospital) to elucidate the neuronal mechanisms underlying cognitive resilience to Alzheimer's disease. The project, awarded on August 15, 2025, aims to (1) determine if the MEF2 transcription factors mediate survival of specific neuronal subtypes vulnerable to Alzheimer's pathology, (2) assess whether...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund a pilot study to evaluate the feasibility of using non-invasive neuroimaging techniques to monitor the metabolic and vascular functions of the brain and heart in a mouse model of Alzheimer's disease (AD). The $332,096 award, with a performance period from July 2024 to June 2026, will be made to The General Hospital Corporation (doing business as Massachusetts General Hospital). The research aims to elucidate the effect of moderate exercise on AD pathogenesis, including any gender differences, by assessing changes in cardiac and cerebral blood flow, mitochondrial function, and oxidative stress. The proposed multi-modal imaging approach has direct translational value for advancing human AD research and improving understanding of the interplay between cardiovascular and metabolic health in this neurodegenerative disease.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $332.1k | 7/2/24 |